510 related articles for article (PubMed ID: 25552385)
21. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM
Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593
[TBL] [Abstract][Full Text] [Related]
22. Aromatase inhibitors and their antitumor effects in model systems.
Brodie A; Lu Q; Liu Y; Long B
Endocr Relat Cancer; 1999 Jun; 6(2):205-10. PubMed ID: 10731110
[TBL] [Abstract][Full Text] [Related]
23. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium.
Labrie F; Labrie C; Bélanger A; Simard J; Gauthier S; Luu-The V; Mérand Y; Giguere V; Candas B; Luo S; Martel C; Singh SM; Fournier M; Coquet A; Richard V; Charbonneau R; Charpenet G; Tremblay A; Tremblay G; Cusan L; Veilleux R
J Steroid Biochem Mol Biol; 1999; 69(1-6):51-84. PubMed ID: 10418981
[TBL] [Abstract][Full Text] [Related]
24. A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.
Thrane S; Pedersen AM; Thomsen MB; Kirkegaard T; Rasmussen BB; Duun-Henriksen AK; Lænkholm AV; Bak M; Lykkesfeldt AE; Yde CW
Oncogene; 2015 Aug; 34(32):4199-210. PubMed ID: 25362855
[TBL] [Abstract][Full Text] [Related]
25. FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4.
McClements L; Annett S; Yakkundi A; O'Rourke M; Valentine A; Moustafa N; Alqudah A; Simões BM; Furlong F; Short A; McIntosh SA; McCarthy HO; Clarke RB; Robson T
BMC Cancer; 2019 Apr; 19(1):351. PubMed ID: 30975104
[TBL] [Abstract][Full Text] [Related]
26. Guide-lines in the design of new antiestrogens and cytotoxic-linked estrogens for the treatment of breast cancer.
Leclercq G; Devleeschouwer N; Heuson JC
J Steroid Biochem; 1983 Jul; 19(1A):75-85. PubMed ID: 6887875
[TBL] [Abstract][Full Text] [Related]
27. Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment.
Goto W; Kashiwagi S; Asano Y; Takada K; Morisaki T; Takahashi K; Fujita H; Shibutani M; Amano R; Takashima T; Tomita S; Hirakawa K; Ohira M
BMC Cancer; 2020 Dec; 20(1):1215. PubMed ID: 33302911
[TBL] [Abstract][Full Text] [Related]
28. Estrogen inhibits the growth of estrogen receptor-negative, but not estrogen receptor-positive, human mammary epithelial cells expressing a recombinant estrogen receptor.
Zajchowski DA; Sager R; Webster L
Cancer Res; 1993 Oct; 53(20):5004-11. PubMed ID: 8402691
[TBL] [Abstract][Full Text] [Related]
29. Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin.
Vanderlaag KE; Hudak S; Bald L; Fayadat-Dilman L; Sathe M; Grein J; Janatpour MJ
Breast Cancer Res; 2010; 12(3):R32. PubMed ID: 20525379
[TBL] [Abstract][Full Text] [Related]
30. Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells.
Watts CK; Sweeney KJ; Warlters A; Musgrove EA; Sutherland RL
Breast Cancer Res Treat; 1994; 31(1):95-105. PubMed ID: 7981461
[TBL] [Abstract][Full Text] [Related]
31. ER-α variant ER-α36 mediates antiestrogen resistance in ER-positive breast cancer stem/progenitor cells.
Deng H; Yin L; Zhang XT; Liu LJ; Wang ML; Wang ZY
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():417-26. PubMed ID: 25158023
[TBL] [Abstract][Full Text] [Related]
32. A suppressive role of guanine nucleotide-binding protein subunit beta-4 inhibited by DNA methylation in the growth of anti-estrogen resistant breast cancer cells.
Wang B; Li D; Rodriguez-Juarez R; Farfus A; Storozynsky Q; Malach M; Carpenter E; Filkowski J; Lykkesfeldt AE; Kovalchuk O
BMC Cancer; 2018 Aug; 18(1):817. PubMed ID: 30103729
[TBL] [Abstract][Full Text] [Related]
33. Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Cancer.
Smith JW; Vukelja S; Hoffman AD; Jones VE; McIntyre K; Berrak E; Song JX; O'Shaughnessy J
Clin Breast Cancer; 2016 Feb; 16(1):31-7. PubMed ID: 26433876
[TBL] [Abstract][Full Text] [Related]
34. Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models.
Niwa Y; Asano M; Nakagawa T; France D; Semba T; Funahashi Y
Anticancer Res; 2020 Dec; 40(12):6699-6712. PubMed ID: 33288563
[TBL] [Abstract][Full Text] [Related]
35. Antitumor activity of a novel antiestrogen (Analog II) on human breast cancer cells.
Jain PT; Rajah TT; Pento JT
Anticancer Drugs; 1997 Nov; 8(10):964-73. PubMed ID: 9436640
[TBL] [Abstract][Full Text] [Related]
36. Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens.
Wilcken NR; Prall OW; Musgrove EA; Sutherland RL
Clin Cancer Res; 1997 Jun; 3(6):849-54. PubMed ID: 9815758
[TBL] [Abstract][Full Text] [Related]
37. Effects of fulvestrant alone or combined with different steroids in human breast cancer cells in vitro.
Jansen GH; Franke HR; Wolbers F; Brinkhuis M; Vermes I
Climacteric; 2008 Aug; 11(4):315-21. PubMed ID: 18645697
[TBL] [Abstract][Full Text] [Related]
38. Eribulin mesylate.
Jain S; Vahdat LT
Clin Cancer Res; 2011 Nov; 17(21):6615-22. PubMed ID: 21859830
[TBL] [Abstract][Full Text] [Related]
39. Downregulation of retinoblastoma protein is involved in the enhanced cytotoxicity of 4-hydroxytamoxifen plus mifepristone combination therapy versus antiestrogen monotherapy of human breast cancer.
Schoenlein PV; Hou M; Samaddar JS; Gaddy VT; Thangaraju M; Lewis J; Johnson M; Ganapathy V; Kallab A; Barrett JT
Int J Oncol; 2007 Sep; 31(3):643-55. PubMed ID: 17671693
[TBL] [Abstract][Full Text] [Related]
40. PI3K activation promotes resistance to eribulin in HER2-negative breast cancer.
Gris-Oliver A; Ibrahim YH; Rivas MA; García-García C; Sánchez-Guixé M; Ruiz-Pace F; Viaplana C; Pérez-García JM; Llombart-Cussac A; Grueso J; Parés M; Guzmán M; Rodríguez O; Anton P; Cozar P; Calvo MT; Bruna A; Arribas J; Caldas C; Dienstmann R; Nuciforo P; Oliveira M; Cortés J; Serra V
Br J Cancer; 2021 Apr; 124(9):1581-1591. PubMed ID: 33723394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
